Tailored Diarylalkane Solutions for Specialized Skin Care Needs

Publication ID: 24-11857657_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Tailored Diarylalkane Solutions for Specialized Skin Care Needs,” Published Technical Disclosure No. 24-11857657_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857657_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,657.

Summary of the Inventive Concept

This inventive concept adapts diarylalkane-based compositions for specific, niche skin care applications, including high-altitude environments, sensitive skin, albinism, vitiligo, and dark skin tones. These specialized solutions address unmet needs in these markets, providing targeted and effective treatments for skin pigmentation, melanin synthesis, and skin damage.

Background and Problem Solved

The original patent disclosed diarylalkane-based compositions for treating skin pigmentation due to inflammatory conditions. However, these compositions may not be suitable for specific, niche markets with unique operational environments or skin characteristics. The present inventive concept addresses these limitations by developing tailored solutions that cater to these special needs, ensuring effective and safe treatments.

Detailed Description of the Inventive Concept

The new inventive concept comprises five specialized variations of diarylalkane-based compositions, each designed to address a specific skin care need. The first variation is a system for treating skin pigmentation in high-altitude environments, where low oxygen levels can affect composition stability. The second variation is a method for inhibiting melanin synthesis in individuals with sensitive skin, using a transdermal patch formulation to minimize skin irritation. The third variation is a composition for treating skin discoloration in individuals with albinism, formulated to enhance skin penetration in compromised skin barriers. The fourth variation is a system for preventing skin damage from UV radiation in individuals with vitiligo, providing enhanced photoprotection. The fifth variation is a method for treating skin hyperpigmentation in individuals with dark skin tones, using a topical formulation that minimizes skin whitening and promotes even skin tone.

Novelty and Inventive Step

The new claims introduce novel and non-obvious adaptations of diarylalkane-based compositions for specific, niche skin care applications. These adaptations involve unique formulations, delivery systems, and operational environments that depart from the original patent's disclosures. The inventive step lies in recognizing the need for tailored solutions in these specialized markets and developing targeted compositions that address these needs.

Alternative Embodiments and Variations

Other possible embodiments of the inventive concept could include diarylalkane-based compositions for treating skin conditions in extreme weather environments, such as desert or tropical climates. Additionally, the inventive concept could be adapted for use in cosmetic products, such as sunscreens or moisturizers, to provide enhanced skin protection and care.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the skincare industry, particularly in niche markets with unmet needs. Target industries include pharmaceutical companies, cosmetic manufacturers, and dermatology clinics. The specialized solutions offered by the inventive concept could provide a competitive edge in these markets, addressing specific skin care needs and improving treatment outcomes.

CPC Classifications

SectionClassGroup
A A61 A61K8/347
A A61 A61K8/31
A A61 A61K8/4973
A A61 A61K8/9789
A A61 A61K8/9794
A A61 A61K31/015
A A61 A61K31/05
A A61 A61K31/085
A A61 A61K31/09
A A61 A61K31/357
A A61 A61K31/40
A A61 A61K31/704
A A61 A61Q19/02
C C07 C07C39/15
C C07 C07C39/367
C C07 C07C41/26
C C07 C07C41/32
C C07 C07C43/23
C C07 C07C45/673
C C07 C07C49/835
C C07 C07C215/74
C C07 C07D321/12
A A61 A61K2800/782
Y Y02 Y02A50/30

Field of Art

Dermatological compositions and methods for skin treatment, specifically focused on pigmentation modulation, enzyme inhibition, and topical drug delivery systems

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist or dermatological researcher with expertise in organic chemistry, skin biology, drug delivery technologies, and experience in developing topical therapeutic compositions

Obviousness Rationale

A PHOSITA would recognize that the source patent's diarylalkane compositions provide a foundational framework for targeted skin treatments, and the PTD's variations represent predictable extensions of known therapeutic strategies by adapting delivery mechanisms and targeting specific patient populations with minor formulation modifications.

Obvious Combinations & Variations

Source Patent Element
Diarylalkane compounds for treating skin pigmentation and inhibiting melanin synthesis
PTD Variation
Specialized formulations for high-altitude environments with low-oxygen stability modifications
Obviousness Reasoning
A PHOSITA would understand that environmental stability can be achieved through standard pharmaceutical formulation techniques like adding stabilizing agents or modifying molecular structure to resist degradation
Source Patent Element
Topical administration of diarylalkane compositions for skin treatment
PTD Variation
Transdermal patch formulation for sensitive skin to minimize irritation
Obviousness Reasoning
Transdermal drug delivery is a known technique for reducing systemic side effects, and a PHOSITA would find it obvious to adapt the source patent's composition to a patch delivery system
Source Patent Element
Methods for treating skin discoloration and pigmentation disorders
PTD Variation
Compositions specifically targeting albinism and vitiligo patient populations
Obviousness Reasoning
Tailoring pharmaceutical compositions to specific patient populations represents a standard design choice in therapeutic development, utilizing known active compounds with modified delivery strategies
Source Patent Element
Skin treatment compositions that neutralize active oxygen species
PTD Variation
Enhanced photoprotection formulations for individuals with specific skin conditions
Obviousness Reasoning
Modifying antioxidant compositions to provide UV protection is a predictable variation within the known capabilities of diarylalkane compounds
Source Patent Element
Skin tone evening and pigmentation reduction methods
PTD Variation
Topical formulations designed to minimize skin whitening in dark skin tones
Obviousness Reasoning
Adjusting pharmaceutical compositions to provide more nuanced therapeutic effects represents an expected progression in dermatological treatment design
35 U.S.C. § 103 Summary: Based on US Patent 11857657's disclosure of diarylalkane compositions for skin treatment, the present publication demonstrates that the claimed variations represent obvious extensions of the prior art through predictable modifications in formulation, delivery mechanism, and targeted patient populations, thus rendering subsequent claims of novelty invalid under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,657
TitleDiarylalkanes as potent inhibitors of binuclear enzymes
Assignee(s)Unigen, Inc.